|
Spero Therapeutics, Inc. (SPRO) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Spero Therapeutics, Inc. (SPRO) Bundle
Unser DCF-Taschenrechner von Spero Therapeutics, Inc. (SPRO) (Spero Therapeutics, Inc.) ermöglicht es Ihnen, die Bewertung von Spero-Therapeutika mit realen Finanzdaten und der vollständigen Flexibilität zu bewerten, um alle wesentlichen Parameter für erweiterte Projektionen zu ändern.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.7 | 9.3 | 18.3 | 48.6 | 96.7 | 191.4 | 378.8 | 749.6 | 1,483.4 | 2,935.5 |
| Revenue Growth, % | 0 | 96.75 | 95.67 | 166.1 | 99.13 | 97.89 | 97.89 | 97.89 | 97.89 | 97.89 |
| EBITDA | -62.5 | -76.9 | -87.2 | -42.3 | 25.8 | -138.0 | -273.0 | -540.3 | -1,069.1 | -2,115.6 |
| EBITDA, % | -1317.29 | -824.59 | -477.49 | -87 | 26.64 | -72.07 | -72.07 | -72.07 | -72.07 | -72.07 |
| Depreciation | 1.2 | 1.3 | 1.1 | 1.5 | .4 | 18.6 | 36.8 | 72.8 | 144.0 | 284.9 |
| Depreciation, % | 24.42 | 14.43 | 6.12 | 3.18 | 0.37939 | 9.71 | 9.71 | 9.71 | 9.71 | 9.71 |
| EBIT | -63.6 | -78.3 | -88.3 | -43.8 | 25.4 | -139.3 | -275.7 | -545.6 | -1,079.7 | -2,136.6 |
| EBIT, % | -1341.71 | -839.01 | -483.61 | -90.18 | 26.26 | -72.78 | -72.78 | -72.78 | -72.78 | -72.78 |
| Total Cash | 82.0 | 126.9 | 146.4 | 109.1 | 76.3 | 183.4 | 362.8 | 718.0 | 1,420.8 | 2,811.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 8.5 | 6.2 | 2.6 | 1.1 | 50.7 | 90.1 | 178.3 | 352.8 | 698.1 | 1,381.4 |
| Account Receivables, % | 180.22 | 66.2 | 14.47 | 2.23 | 52.41 | 47.06 | 47.06 | 47.06 | 47.06 | 47.06 |
| Inventories | -13.4 | -12.2 | .0 | -4.5 | .0 | -80.1 | -158.5 | -313.6 | -620.6 | -1,228.1 |
| Inventories, % | -281.93 | -131.18 | 0 | -9.19 | 0 | -41.84 | -41.84 | -41.84 | -41.84 | -41.84 |
| Accounts Payable | 4.1 | 1.2 | 1.1 | .6 | 1.4 | 41.6 | 82.2 | 162.8 | 322.1 | 637.3 |
| Accounts Payable, % | 87.45 | 12.38 | 6.03 | 1.27 | 1.42 | 21.71 | 21.71 | 21.71 | 21.71 | 21.71 |
| Capital Expenditure | -.3 | -.2 | .0 | .0 | .0 | -3.2 | -6.3 | -12.5 | -24.6 | -48.8 |
| Capital Expenditure, % | -6.62 | -1.68 | 0.21363 | 0 | 0 | -1.66 | -1.66 | -1.66 | -1.66 | -1.66 |
| Tax Rate, % | 10.23 | 10.23 | 10.23 | 10.23 | 10.23 | 10.23 | 10.23 | 10.23 | 10.23 | 10.23 |
| EBITAT | -62.8 | -77.5 | -89.8 | -45.3 | 22.8 | -135.9 | -268.9 | -532.0 | -1,052.8 | -2,083.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -53.0 | -78.1 | -97.4 | -38.2 | -30.1 | -39.6 | -207.5 | -410.6 | -812.5 | -1,607.9 |
| WACC, % | 6.56 | 6.56 | 6.57 | 6.57 | 6.52 | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2,360.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1,640 | |||||||||
| Terminal Value | -36,004 | |||||||||
| Present Terminal Value | -26,211 | |||||||||
| Enterprise Value | -28,571 | |||||||||
| Net Debt | -71 | |||||||||
| Equity Value | -28,500 | |||||||||
| Diluted Shares Outstanding, MM | 53 | |||||||||
| Equity Value Per Share | -537.85 |
What You Will Get
- Real Spero Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Spero Therapeutics, Inc. (SPRO).
- Full Customization: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates specific to Spero Therapeutics.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Spero Therapeutics, Inc.'s (SPRO) fair value.
- Versatile Excel Template: Designed for quick edits, scenario testing, and detailed projections tailored for Spero Therapeutics.
- Time-Saving and Accurate: Eliminate the need to build models from scratch while ensuring precision and flexibility for Spero Therapeutics, Inc. (SPRO).
Key Features
- Comprehensive SPRO Data: Pre-filled with Spero Therapeutics’ historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth rates, profit margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Develop multiple forecasting scenarios to evaluate different valuation outcomes.
- User-Friendly Design: Intuitive, structured, and tailored for both professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Spero Therapeutics, Inc.'s pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you adjust your assumptions.
- Step 5: Analyze the outputs and utilize the results for investment decisions regarding Spero Therapeutics, Inc. (SPRO).
Why Choose This Calculator for Spero Therapeutics, Inc. (SPRO)?
- Accurate Data: Real-time Spero Therapeutics financials provide trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Built-in calculations save you from starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech industry.
- User-Friendly: Easy-to-navigate layout and clear instructions ensure accessibility for all users.
Who Should Use This Product?
- Individual Investors: Gain insights to make informed decisions regarding Spero Therapeutics, Inc. (SPRO) stock transactions.
- Financial Analysts: Enhance valuation methodologies with accessible financial models tailored for Spero Therapeutics, Inc. (SPRO).
- Consultants: Provide clients with precise and timely valuation analysis for Spero Therapeutics, Inc. (SPRO).
- Business Owners: Learn how biopharmaceutical companies like Spero Therapeutics, Inc. (SPRO) are valued to inform your own business strategies.
- Finance Students: Acquire practical valuation skills using real-world examples from Spero Therapeutics, Inc. (SPRO).
What the Template Contains
- Pre-Filled Data: Includes Spero Therapeutics’ historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automated calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC using custom inputs.
- Key Financial Ratios: Analyze Spero Therapeutics’ profitability, efficiency, and leverage.
- Customizable Inputs: Easily edit revenue growth, margins, and tax rates.
- Clear Dashboard: Visuals and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.